PODD: Partnership Opportunities in Drug Delivery

Published on :

Pharma, biotech and the drug delivery industries gather annually at PODD to assess delivery needs, latest trends and information on deals and learn about a wide range of innovative drug [….]

Luke Thorstenson Appointed Director of Business Development for Orgenesis Inc.

Published on :

Orgenesis Inc., a global biotech company working to unlock the full potential of cell and gene therapies, has appointed Luke Thorstenson as Director of Business Development. As Director of Business Development, his core responsibilities include setting the strategy for major Cell and Gene Therapy (CGT) initiatives and implementing the Orgenesis point-of-care platform in the United States. In addition, he will identify global opportunities for growth and analyze the development of value creation units and business units. He will also manage and establish new partnerships with research institutions like Johns Hopkins University, including the launch of several CGT specific facilities here in Baltimore

2021 Technology Showcase

Published on :

Hear from inventors from the National Cancer Institute and the Frederick National Laboratory about technologies primed for commercialization and/or collaboration; great opportunity for biotech stakeholders and companies of all sizes, [….]

NCI Tech Opportunities Webinar: New HIV Vaccine to Treat and Prevent HIV

Published on :

TTC is planning a technology opportunities webinar on July 13, 2021 from 11:00 am – noon, EST. Attendees will hear from the NCI’s Dr. Genoveffa Franchini about a new HIV [….]

NCI Technology Opportunities Webinar: “Complete Tumor Regression Seen in Colon Cancer and Leukemia Animal Models with a Novel High Efficacy Fluorinated Cytidine Therapeutic Compound”

Published on :

The National Cancer Institute (NCI), Technology Transfer Center (TTC) will host a webinar to highlight a cancer therapeutic technology for collaborative development and/or licensing. The webinar presented by the technology inventor, Dr. Joel Morris, will highlight NCI’s novel, therapeutic fluorinated cytidine compound that shows high efficacy against colon cancer and leukemia. Studies indicated that the therapeutic compound can produce complete regression in xenograph mouse models with minimal effects on body weight. Registration is free.

5 Questions with Stephen M. Jackson, Staff Scientist – Immunology, ABL, Inc.

Published on :

Born and raised in gang-infested South Central Los Angeles, I was surrounded by compassionate and risk-taking individuals who recognized and fertilized my love, talent, and academic prowess. Collectively my tribe, for it takes one to raise one, helped provide me with unimaginable opportunities to excel and continue the fight for an abundant life through health, social awareness, and artistic expression. I, a Man who is also Bold and Black, am a product of their courage, compassion, endurance, vision, and love – Stephen M. Jackson, PhD

Virtual DC Startup Showcase @ GW

Published on :

The George Washington University (GW) Technology Commercialization Office is pleased to host the inaugural DC Startup Showcase.DC Startup Showcase will present companies developing disruptive healthcare innovations. Log on to our [….]